Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$205.70-1.32%
Close 2026-07-07 · 1-day change
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→QuarterlyIQ Insights · BIIB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 57.9% avg surprise
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 50% of the time over the next year (vs 42% for the rest of the cohort, n=9129).
Over the trailing year it converted 1.89x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 49% of the time over the next year (vs 41% for the rest of the cohort, n=3127).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.